NCT04050865View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Dexamethasone, 0.4mg

Ophthalmic Insert

DEVICE

Placebo plug with no drug

Ophthalmic Insert

Trial Locations (6)

38119

Total Eye Care, P.A., Memphis

40206

The Eye Care Institute, Louisville

64133

Silverstein Eye Centers, Kansas City

78681

Eye Associates of Texas, Round Rock

80907

Vision Institute, Colorado Springs

02767

Andover Eye Associates, Raynham

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY

NCT04050865 - A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter